What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug1: SH3765 will be administered orally twice daily on an intermittent dosing schedule with treatment on Days 1 to 4 each week of a 28-day treatment cycle. The dosage is 40 mg or 60mg twice daily (BID) (4 days on and 3 days off). Drug2:Fulvestrant injection is to be administered after taking the SH3765 tablets. It is given intramuscularly at a dose of 500 mg on Day 1 and Day 15 of Cycle 1, and…”In the company’s words, NCT07557004 on ClinicalTrials.gov
- Tested for
- HR+ / HER2- Advanced Breast Cancer
- Main trialPhase 1
- “Evaluate the efficacy and safety of the SH3765 tablet combined with fulvestrant in the treatment of patients with advanced HR-positive breast cancer”In the company’s words, NCT07557004 on ClinicalTrials.gov
Coming up1
- 30 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 30 Jun 2027 | A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. | |
| Phase 1Unknown | Mar 2023 | A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026